Bernstein Raises its Price Target on CRISPR Therapeutics (CRSP)

CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the 10 Best European Growth Stocks to Buy.

On May 13, 2026, Bernstein raised the firm’s price target on CRISPR Therapeutics AG (NASDAQ:CRSP) to $56 from $50 while maintaining a Market Perform rating on the shares. Bernstein said the biotech sector has started 2026 strongly, with the group up 11% year-to-date and outperforming both large-cap pharma and the broader S&P 500. The firm added that smaller biotech companies have led the rally and maintained a constructive view on the sector, citing expectations for continued healthy M&A and IPO activity alongside recent FDA leadership changes that could benefit earlier-stage biotech companies.

Meanwhile, BofA lowered the firm’s price target on CRISPR Therapeutics AG (NASDAQ:CRSP) to $83 from $86 while maintaining a Buy rating on the shares. The firm said it came away from the company’s first-quarter updates with “few changes to the core thesis,” describing the overall developments as encouraging.

Bernstein Raises its Price Target on CRISPR Therapeutics (CRSP)

15 States with the Best Healthcare in the US

On May 4, 2026, CRISPR Therapeutics AG (NASDAQ:CRSP) reported that first-quarter revenue totaled $1.4M. Chairman and CEO Samarth Kulkarni said the quarter reflected continued execution across the company’s broader gene-editing platform. Kulkarni highlighted the expansion of zugo-cel into additional autoimmune disease indications and continued progress advancing several in vivo liver-directed programs toward clinical development. The company also pointed to continued momentum for CASGEVY. Management added that with a strengthened balance sheet and multiple upcoming catalysts, 2026 could become a defining year for the company.

CRISPR Therapeutics AG (NASDAQ:CRSP) develops gene-editing therapies for serious diseases using its CRISPR/Cas9 platform technology.

While we acknowledge the risk and potential of CRSP as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than CRSP and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1